ELTX Elicio Therapeutics Inc

$ELTX I just doubled down here. I think the re-rating has run its course, and given that MOS from the previous trial is still evolving, Checkpoint + vaccine looks very encouraging, and the technology is very robust across many indications. I think this is a very interesting entry point.

$ELTX New Phase 1 combination trial expected in Q4 2026 and targeting metastatic pancreatic cancer..

$ELTX Darrell Irvine presenting AMPLIFY-7P clinical results in a plenary session at SITC 2026. The fact that these results have been selected for presentation at both ESMO and SITC gives me hope that we are looking at something truly meaningful. And let us not overlook who is presenting them: two heavyweights in their respective fields. Both Eileen O’Reilly and Darrell Irvine are among the very best at what they do. There will also be a poster presentation on Elicio AIM technology. I highly recommend reading the presentation available on the company website. Very interesting stuff.

$ELTX ESMO: two possibilities: (1) OS from AMPLIFY-7P (2) A clearer responder phenotype / biological analysis that connects ELI-002 activity to the metastatic checkpoint hypothesis....

$ELTX company needs to provide an update on combo tx with CPI. Think this has potential in both CRC and PDAC but not as monotherapy.

$ELTX would be nice to hear of any updates including the possibility of incorporating camupepimut with KRAS inhibitors.